|
|
|
|
|
PRESS RELEASE - 2003 |
 | |
July 2003
BioGenex to Expand Customer Support Services with MERA®
May 2003
BioGenex Introduces Antibody Against CA125 Antibody, An ovarian Tumor Marker
May 2003
BioGenex Introduces Antibody to CD4, A Potential Marker for Elucidating the Role of Cell Surface Receptors in the Immune Response
May 2003
BioGenex Introduces Anti-CD8 Antibody, A Stage Marker of T-cell Development
May 2003
BioGenex Introduces Anti-gM Antibody, which in conjunction with IgD Antibody can be used to Distinguish whether a B-Cell Lymphoma is Derived from Mantle or Marginal Zones
May 2003
BioGenex Introduces Banti-Myeloperoxidase Antibody, A Marker for Acute Myeloid Leukemia, Also Implicated in Diseases of Atherosclerosis, Lung cancer, Alzheimer’s, and Multiple Sclerosis
May 2003
BioGenex Introduces anti-p63 Antibody for Differential Diagnosis of Benign and Malignant Prostatic Lesions
April 2003
BioGenex Introduces anti-CA19-9 Antibody, A Valuable Indicator of Tumor Occurrence Expressed in Tumor Cells of Colorectal, Gastric and Pancreatic Carcinomas
April 2003
BioGenex Introduces Anti-Mast Cell Tryptase Antibody, A Potential Indicator of Several Mast Cell-Related Allergic and Inflammatory Conditions
April 2003
BioGenex Introduces anti-Tau Antibody for Detecting Neurofibrillary Lesions Characterizing Alzheimer’s Disease
April 2003
BioGenex Announces Super Sensitive? Non-Biotin HRP Detection System
April 2003
InnoGenex, a Subsidiary of BioGenex, Introduces Human Lung Cancer Tissue Microarrays for High Throughput Screening of In Situ Gene Expression Analysis
February 2003
InnoGenex, a Subsidiary of BioGenex, Introduces Human Breast Cancer Tissue Microarrays for High Throughput Screening of In Situ Gene Expression Analysis
January 2003
InnoGenex, a Subsidiary of BioGenex, Introduces Human Colorectal Cancer Tissue Microarrays for High Throughput Screening of In Situ Gene Expression Analysis
|
|
